Tourmaline Bio (NASDAQ: TRML) reported Q2 2025 financial results and highlighted significant progress in its clinical programs. The company announced positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug, demonstrating rapid and significant reductions in high-sensitivity C-reactive protein with quarterly dosing.
Key financial metrics include cash position of $256.4 million as of June 30, 2025, providing runway into H2 2027. Q2 2025 saw net loss of $23.1 million ($0.90 per share), with R&D expenses at $19.6 million and G&A expenses at $6.3 million.
The company plans to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in H2 2025 and is preparing for a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease. Additional TRANQUILITY trial data will be presented at the upcoming European Society of Cardiology Congress.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.